adplus-dvertising
Connect with us

Investment

IRICoR and the Quebec Breast Cancer Foundation: Joint $3M investment for new treatments – Canada NewsWire

Published

 on


MONTREAL, July 14, 2020 /CNW Telbec/ – The pandemic has highlighted the importance of supporting scientific research in order to allow investigators to find real solutions to deal with public health issues such as COVID-19 or cancer. In this context, IRICoR and the Quebec Breast Cancer Foundation (QBCF) have joined forces to fund research on breast cancer, a cancer that affects a large and vulnerable population. Today, they proudly announce the four recipients of their joint LeadAction|Breast Cancer du Sein Competition, launched across Canada. These winning investigators from Quebec will benefit from a total amount of 3 million dollars over three years, with $1.5M coming from IRICoR and $1.5M from the QBCF.

This substantial support will enable recipients to accelerate their innovative breast cancer research work in order to offer more therapeutic options to those affected. The projects selected target two major breast cancer issues: 

  1. Understanding why certain types of breast cancer are treatment-resistant and thus fight these resistance mechanisms with new therapies.
  2. Developing new treatments for aggressive types of breast cancer, such as triple-negative and HER2-dependent.

“The LeadAction|Breast Cancer du Sein Competition is unique and innovative! It is translated by the convergence of three vital scientific and social innovation components, namely science, industry and the patient community. Therefore, by jointly launching this call, IRICoR and the Quebec Breast Cancer Foundation have met the glaring needs of the people affected by breast cancer, by supporting large-scale projects that will result in developing new promising therapies”, points out Jida El Hajjar, Ph.D., Vice-President of Investment and Health Promotion at the QBCF. 

300x250x1


“Leading-edge breast cancer research must effectively translate into benefits to patients. The LeadAction|Breast Cancer du Sein Competition represents an exceptional opportunity to support creative projects that will ensure the development of novel therapeutic solutions for those suffering from breast cancer. This Competition allows us to seize the opportunity of combining our expertise in transforming research into therapeutic innovations with respect to the needs of breast cancer patients. IRICoR is excited about the outstanding quality of the projects submitted as part of the LeadAction|Breast Cancer du sein Competition launched across Canada“, added Dr. Nadine Beauger, Ph.D., MBA, Chief Executive Officer of IRICoR.

Recipients of the LeadAction|Breast Cancer du Sein Competition

Following a competitive process and a thorough assessment of applications from Quebec and the rest of Canada by an independent international peer committee, four projects were selected:

1.  Blocking the addictions of cancerous tumors in order to destroy them

Rationally designed approaches to target mRNA translation in eradicating poor outcome breast cancers [Team headed by Jerry Pelletier, Principal Investigator at the Goodman Cancer Research Centre, McGill University] 

While cancer cells depend on the translation of mRNA to produce the proteins required for their aggressive nature, no molecule has yet been developed to block that process in breast cancer. The team headed by Jerry Pelletier seeks to remedy that situation by developing a molecule belonging to a whole new class of anti-cancer agent that can target and block that addiction.

2.  Countering resistance to treatments 

Development of orally bioavailable antiestrogens optimized for induction of estrogen receptor post-translational modifications by SUMOylation [Team headed by Sylvie Mader, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal]

30 to 50% of patients affected by hormone-dependent (ER+) breast cancer develop resistance to therapies targeting the estrogen receptor. This team has already discovered that SUMOylation of the estrogen receptor contributes to the efficacy of fulvestrant, an anti-estrogen used in the treatment of ER+ breast cancer progressing after hormonal therapy. They are now working on developing new molecules optimized for this activity to better treat those affected by ER+ metastatic breast cancer.

3.  Demystifying the role of a protein responsible for the spread of triple-negative breast cancer

Development of small-molecule inhibitors of Ran GTPase as anti-cancer agents [Team headed by Anne-Marie Mes-Masson, Principal Investigator at the CHUM Research Centre]

Breast cancer is much more difficult to treat at the metastatic stage. In many cases, the protein Ran is associated with the spread of the disease to the other healthy tissues. The two investigators are currently testing molecules to curb the protein Ran for the purpose of slowing down or stopping the progression of breast cancer.

 4.  Developing a new molecule comparable to vitamin D to fight triple-negative breast cancer

Bifunctional vitamin D analogues as novel therapeutics against triple-negative breast cancer [Team headed by John White, Principal Investigator at the Lady Davis Institute, Jewish General Hospital]

This team of investigators developed a new class of molecules as therapeutic agents against triple-negative breast cancer. They are vitamin D analogues. Their distinctive feature: they combine 2 active functions against cancer, namely HDAC inhibitors and the active form of vitamin D.

About IRICoR

Designated as a Centre of Excellence in Research and Commercialization (CECR) by the Canadian government and based at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, IRICoR is a pan-Canadian leader in the de-risking of early-stage assets in the field of drug discovery. IRICoR’s mandate is to accelerate the discovery, development, and commercialization of novel therapies in cancer and rare diseases. Since 2008, IRICoR has been successfully investing in and supporting selected high-value projects in order to rapidly translate early-stage innovation into potential new therapies, through either co-development partnerships with the biopharmaceutical industry or the creation of spin-off companies. IRICoR seamlessly combines its business-related expertise with access to industry-level drug discovery capabilities, providing selected academic and industry projects with access to its network of experts and cutting-edge infrastructure, including one of the largest academia-based drug discovery unit in Canada. IRICoR’s major funding sources include the federal CECR Program, the Ministère de l’Économie et de l’Innovation du Québec (MEI), and collaborative partnerships with the biopharmaceutical industry.

For more information about IRICoR: iricor.ca 

About the Quebec Breast Cancer Foundation

The Quebec Breast Cancer Foundation (QBCF) is dedicated to achieving its vision: a breast cancer free future. Breast cancer milestones underline the importance of our MISSION: advancing leading-edge research, education, community support, and advocacy. Since 1994, QBCF has raised more than $46 million to support promising research leading to key breakthroughs in breast cancer screening, diagnosis, treatment, survivorship, and end-of life care. Our role as catalyst for establishing strategic collaborations brought cancer institutions, health professionals, and researchers to adopt interesting innovations such as artificial intelligence, telehealth, 3-D printing, big data, and many more. Together with our researchers, volunteers, supporters, stakeholders and staff, we are committed to continue our mission and to transform breast cancer control.

For more information about the Quebec Breast Cancer Foundation: rubanrose.org/en

SOURCE IRICOR

For further information: For further information or interviews: Marie-Pier Cornellier, Media Relations and Communications Specialist, Quebec Breast Cancer Foundation, 819 572-1254, [email protected] ; Noémie Desbois Mackenzie, Communication Advisor, Public Relations, IRICoR, 514 475-7682, [email protected]

Related Links

https://www.iricor.ca/fr/

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Investment

MOF: Govt to establish high-level facilitation platform to oversee potential, approved strategic investments

Published

 on

KUALA LUMPUR: A meeting with 70 financial fund investors and corporate members at the recently concluded Joint Investors Meeting in London has touched on the MADANI government’s immediate action to stimulate strategic investment in important technologies, according to the Ministry of Finance (MoF).

In a statement today, it said that the government is serious about making investments a national agenda through the establishment of a high-level investment facilitation platform to ensure the implementation of potential and approved strategic investments through a “Whole of Government” approach.

Minister of Finance II Datuk Seri Amir Hamzah Azizan (pix), who led the Malaysian delegation to the Joint Investors Meeting from April 20 to 22, said that the National Investment Council (MPN) chaired by the Prime Minister is an integrated action that reflects how serious the government is in making Malaysia an investment hub in the region.

Among the immediate actions taken by the government is establishing the National Semiconductor Strategic Committee (NSSTF) to facilitate cooperation between the government, industry players, universities, and relevant stakeholders to place the Malaysian semiconductor industry at the forefront and ensure the continued growth of the electronics & electrical industry, especially the semiconductor sector, as a major contributor to the Malaysian economy.

300x250x1

The government also aims to empower Malaysia as a preferred green investment destination as well as remove barriers and bureaucracy in the provision and accessibility to renewable energy, especially for the new technology industry, including data centres, said Amir Hamzah.

He also said that the country’s investment prospects have reached an extraordinary level, with approved investments surging to RM329.5 billion in 2023 from RM268 billion in 2022.

He said about 74 per cent of manufacturing projects approved between 2021 and 2023 have been completed or are in process.

In addition, Amir Hamzah said the greater initial stage construction work completed in 2023 (RM31.5 billion) and 2022 (RM26.3 billion) shows a positive trend for future investment opportunities.

“From a total of 5,101 investment projects approved in 2023, as many as 81.2 per cent or 4,143 projects are in the services sector, 883 projects in the manufacturing sector, and 75 projects in other related sectors,” he said.

Before this, Amir Hamzah met with international investors in New York and Washington to clarify the direction of the implementation of the MADANI Economic framework to improve investors’ confidence in Malaysia’s economic level and strengthen the perception and investment sentiment of foreign investors towards the country.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Investment

Want $1 Million in Retirement? Invest $15000 in These 3 Stocks

Published

 on

Compound interest is a thing of magic. It’s also one of your best bets if you’re looking to retire rich.

It might take time and patience but there’s not a whole lot of heavy lifting when it comes to a buy-and-hold investment strategy. What matters most is having decades of time in front of you, which will allow you to maximize the benefits of compounded returns. And, of course, choosing the right investments is equally important.

The magic of compound interest

With a decent return, building a million-dollar portfolio might not be as hard as you think. An initial investment of $15,000, returning 15% annually, would be worth just shy of $1 million in 30 years.

First off, 30 years is a long time, which means you’ll need to be planning your retirement far in advance. However, all it takes is one initial investment of $15,000 and the right stocks to build a $1 million portfolio.

300x250x1

Additionally, it’s important to remain realistic and acknowledge that a stock returning 15% annually is not exactly common. That being said, the TSX certainly has its share of dependable companies with track records of returning far more than just 15% per year.

I’ve put together a list of three Canadian stocks that are perfect for hands-off investors who are looking to retire rich.

Constellation Software

It will require a steep initial investment, but Constellation Software (TSX:CSU) is well worth its nearly $4,000-a-share price tag. When it comes to market-crushing returns, the tech stock has been in a league of its own over the past two decades.

Even as the company is now valued at a massive market cap of close to $80 billion, the impressive returns have continued. Shares are up more than 200% over the past five years. That’s good enough for a compound annual growth rate (CAGR) of 25%.

At a 25% annual return, a $15,000 investment would be worth a whopping $12 million in 30 years.

Descartes Systems

Descartes Systems (TSX:DSG) is another tech stock that’s no stranger to delivering market-beating returns. The company is also only valued at a market cap of $10 billion, leaving plenty of room for growth in the coming decades.

There’s a reason why Descartes Systems is one of the few tech stocks trading near all-time highs today. This stock is a proven winner, with lots of growth left in the tank.

Over the past five years, the stock has had a CAGR just shy of 20%.

goeasy

The last pick on my list is a beaten-down growth stock that’s trading at a serious discount.

The consumer-facing financial services provider has been hit by short-term headwinds from sky-high interest rates. With potential rate cuts around the corner though, now could be an excellent time to be loading up on goeasy (TSX:GSY).

Even with shares down 25% from all-time highs, the stock is still nearing a return of 300% over the past five years.

goeasy was crushing the market’s returns before the recent spike in interest rates, and there’s no reason to believe why the company won’t continue to do so for years to come.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Investment

FLAGSHIP COMMUNITIES REAL ESTATE INVESTMENT TRUST ANNOUNCES CLOSING OF APPROXIMATELY US

Published

 on

TORONTO, April 24, 2024 /CNW/ – Flagship Communities Real Estate Investment Trust (the “REIT” or “Flagship“) (TSX: MHC.U) (TSX: MHC.UN) announced today that it has completed its previously announced public offering (the “Offering“) of 3,910,000 trust units (the “Units“) on a bought deal basis at a price of US$15.35 per Unit for total gross proceeds to the REIT of approximately US$60 million.

The Offering was completed through a syndicate of underwriters co-led by BMO Capital Markets and Canaccord Genuity Corp.

ADVERTISEMENT

The REIT intends to use the net proceeds from the Offering to fund a portion of the approximately US$93 million aggregate purchase price for the REIT’s previously announced acquisition of seven manufactured housing communities comprising 1,253 lots (the “Acquisitions“) and for general business purposes. In the event the REIT is unable to consummate one or both of the Acquisitions, the REIT intends to use the net proceeds of the Offering to fund future acquisitions and for general business purposes.

300x250x1

The REIT has also granted the underwriters an over-allotment option to purchase up to an additional 586,500 Units on the same terms and conditions, exercisable at any time, in whole or in part, up to 30 days after the date hereof.

About Flagship Communities Real Estate Investment Trust

Flagship Communities Real Estate Investment Trust is a leading operator of affordable residential Manufactured Housing Communities primarily serving working families seeking affordable home ownership. The REIT owns and operates exceptional residential living experiences and investment opportunities in family-oriented communities in Kentucky, Indiana, Ohio, Tennessee, Arkansas, Missouri, and Illinois. To learn more about Flagship, visit www.flagshipcommunities.com.

Forward-Looking Statements

This press release contains statements that include forward-looking information (within the meaning of applicable Canadian securities laws). Forward-looking statements are identified by words such as “believe”, “anticipate”, “project”, “expect”, “intend”, “plan”, “will”, “may”, “can”, “could”, “would”, “must”, “estimate”, “target”, “objective”, and other similar expressions, or negative versions thereof, and include statements herein concerning the use of the net proceeds of the Offering.

These forward-looking statements are based on the REIT’s expectations, estimates, forecasts and projections, as well as assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies that could cause actual results to differ materially from those that are disclosed in such forward-looking statements. While considered reasonable by management of the REIT as at the date of this news release, any of these expectations, estimates, forecasts, projections, or assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations, estimates, forecasts, projections, or assumptions could be incorrect. Material factors and assumptions used by management of the REIT to develop the forward-looking information in this news release include, but are not limited to, that the conditions to closing of the Acquisitions will be met or waived in a timely manner and that both of the Acquisitions will be completed on the current agreed upon terms.

When relying on forward-looking statements to make decisions, the REIT cautions readers not to place undue reliance on these statements, as they are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. A number of factors, many of which are beyond the REIT’s control, could cause actual results to differ materially from the results discussed in the forward-looking statements, such as the risks identified in the REIT’s management’s discussion and analysis for the year ended December 31, 2023 available on the REIT’s profile on SEDAR+ at www.sedarplus.com, including, but not limited to, the factors discussed under the heading “Risks and Uncertainties” therein and the risk of the REIT’s plans with respect to debt bridge financing for the Acquisitions not being achieved as anticipated. There can be no assurance that forward-looking statements will prove to be accurate as actual outcomes and results may differ materially from those expressed in these forward-looking statements. Readers, therefore, should not place undue reliance on any such forward-looking statements. Forward-looking statements are made as of the date of this press release and, except as expressly required by applicable Canadian securities laws, the REIT assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Trending